# Validation of Peak Growth Hormone Levels After Clonidine and Glucagon Stimulation Tests in Children With Severe Short Stature

**Authors:** Sridhar Subbiah, Rameez Raja, Dhivya Shanmugam, Sreenivasan Palaniappan, Sreekumar Shanmugam, Muthu Aravind Kumar

PMC · DOI: 10.7759/cureus.100084 · Cureus · 2025-12-25

## TL;DR

This study compares two tests for diagnosing growth hormone deficiency in children and finds optimal timing for blood samples to simplify the process.

## Contribution

The study identifies optimal sampling times for growth hormone tests that maintain diagnostic accuracy while simplifying protocols.

## Key findings

- Peak GH levels occurred at specific times in over 98% of children during both tests.
- Combined CST and GST had perfect diagnostic accuracy for GHD and ISS.
- GST showed higher specificity compared to CST in diagnosing GHD.

## Abstract

Introduction

This study evaluated the concordance and temporal dynamics of growth hormone (GH) responses during the clonidine stimulation test (CST) and glucagon stimulation test (GST) in children being evaluated for growth hormone deficiency (GHD), and identified optimal sampling time points that may allow protocol simplification without compromising diagnostic agreement.

Methods

This prospective study included 55 children who were subjected to CST and GST at a one-week interval. Blood samples for GH were taken at different time intervals following each provocative test per standard protocols. GH levels were estimated by the electrochemiluminescence immunoassay (ECLIA) method. A peak GH level of less than 8 ng/mL was considered diagnostic of GHD.

Results

Among 55 children, 41 were diagnosed with GHD and 14 with idiopathic short stature (ISS). Overall, peak GH levels were noted at 0, 60, and 90 minutes after CST and 0, 120, and 180 minutes after GST in more than 98% of the study cohort. The sensitivity of CST and GST in diagnosing GHD was 87.8% and 90.2%, and the specificity was 85.5% and 100%, respectively. The combined provocative tests (CST and GST) had an area under the curve (AUC) of 1.000, outperforming the individual tests, which had an AUC of 0.914 for CST and 0.987 for GST, to diagnose GHD and ISS.

Conclusions

CST and GST show high concordance in the evaluation of GHD using modern ECLIA-based assays, with GST demonstrating relatively higher specificity. Optimization of sampling time points permits protocol simplification without compromising diagnostic agreement, improving clinical utility.

## Linked entities

- **Chemicals:** clonidine (PubChem CID 2803), glucagon (PubChem CID 16132283)
- **Diseases:** idiopathic short stature (MONDO:1010112)

## Full-text entities

- **Genes:** GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}
- **Diseases:** ISS (MESH:C565805), GHD (MESH:D004393)
- **Chemicals:** Clonidine (MESH:D003000)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12831647/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12831647/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12831647/full.md

---
Source: https://tomesphere.com/paper/PMC12831647